NDLI: Bone-targeting agents in prostate cancer.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Suzman, Daniel L. Boikos, Sosipatros A. Carducci, Michael A.
Description	Country affiliation: United States Author Affiliation: Suzman DL ( Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-1 M45, Baltimore, MD, 21231-1000, USA.)
Abstract	Bone metastases are present in the vast majority of men with advanced prostate cancer, representing the main cause for morbidity and mortality. Recurrent or metastatic disease is managed initially with androgen deprivation but the majority of the patients eventually will progress to castration-resistant prostate cancer, with patients developing bone metastases in most of the cases. Survival and growth of the metastatic prostate cancer cells is dependent on a complex microenvironment (onco-niche) that includes the osteoblasts, the osteoclasts, the endothelium, and the stroma. This review summarizes agents that target the pathways involved in this complex interaction between prostate cancer and bone microenvironment and aim to transform lethal metastatic prostate cancer into a chronic disease.
File Format	HTM / HTML
ISSN	01677659
e-ISSN	15737233
DOI	10.1007/s10555-013-9480-2
Journal	Cancer and Metastasis Reviews
Issue Number	2-3
Volume Number	33
Language	English
Publisher	Springer
Publisher Date	2014-09-01
Publisher Place	Netherlands
Access Restriction	Open
Subject Keyword	Discipline Neoplasms Antineoplastic Agents Pharmacology Therapeutic Use Bone Neoplasms Drug Therapy Bone And Bones Drug Effects Prostatic Neoplasms Pathology Metabolism Clinical Trials As Topic Molecular Targeted Therapy Osteoblasts Osteoclasts Receptors, Androgen Signal Transduction Tumor Microenvironment
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

A multi-targeted approach to treating bone metastases.

Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases.

Novel drugs targeting the androgen receptor pathway in prostate cancer.

Current trials using bone-targeting agents in prostate cancer.

Therapeutic targeting of the prostate cancer microenvironment.

Targeting the androgen receptor in metastatic castration-resistant prostate cancer.

Contemporary therapeutic approaches targeting bone complications in prostate cancer.

Growth factor and signaling pathways and their relevance to prostate cancer therapeutics.

Novel bone-targeting agents in prostate cancer.

Bone-targeting agents in prostate cancer.

Similar Documents

A multi-targeted approach to treating bone metastases.

Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases.

Novel drugs targeting the androgen receptor pathway in prostate cancer.

Current trials using bone-targeting agents in prostate cancer.

Therapeutic targeting of the prostate cancer microenvironment.

Targeting the androgen receptor in metastatic castration-resistant prostate cancer.

Contemporary therapeutic approaches targeting bone complications in prostate cancer.

Growth factor and signaling pathways and their relevance to prostate cancer therapeutics.

Novel bone-targeting agents in prostate cancer.

Bone-targeting agents in prostate cancer.